ANI PHARMACEUTICALS, INC (ANIP) FY2026 YTD Q2 P&L / Income Statement

ANI PHARMACEUTICALS, INC (ANIP) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net Revenues

503,506,000 US dollars

Cost of revenue (calculated)

193,740,000 US dollars

Gross profit (calculated)

309,766,000 US dollars

Operating expenses (calculated)

230,418,000 US dollars

Operating income

79,348,000 US dollars

Other income (expense), net (calculated)

negative 2,030,000 US dollars

Income Before Income Tax Expense

77,318,000 US dollars

Income tax expense

23,115,000 US dollars

Net Income

54,203,000 US dollars

Generics and Other

209,876,000 US dollars

Rare Disease and Brands

293,630,000 US dollars

Cost of sales (excluding depreciation and amortization)

193,740,000 US dollars

Research and development

25,347,000 US dollars

Selling, general, and administrative

165,316,000 US dollars

Depreciation and amortization

40,559,000 US dollars

Contingent consideration fair value adjustment

negative 804,000 US dollars

Generics and Other costs (calculated)

133,064,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Rare Disease and Brands costs (calculated)

205,031,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Reconciling items (calculated)

86,063,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.